“…Quantifying the changes in the preference of the Omicron variant for different entry routes may help evaluate the efficacies of entry inhibitors in clinical development and optimise entry inhibitor-based treatments (Gunst et al, 2021; Zhuravel et al, 2021). Mathematical models of SARS-CoV-2 kinetics have provided valuable insights into COVID-19 disease progression, drug action, and the effectiveness of vaccines and treatments (Amidei and Dobrovolny, 2022; Chatterjee et al, 2022; Desikan et al, 2021; Garg et al, 2021; Gonçalves et al, 2020; Goyal et al, 2020; Ke et al, 2021; Kissler et al, 2021; NĂ©ant et al, 2021; Padmanabhan et al, 2022; Perelson and Ke, 2020). Here, adapting a previously developed mathematical model of SARS-CoV-2 entry (Padmanabhan et al, 2020) to the analysis of in vitro data on variants (Garcia-Beltran et al, 2021; Hoffmann and et al, 2021), we quantified the altered usage of host proteases required for entry by the Omicron variant relative to the original strain and the Delta variant.…”